What Cellino does

Cellino is a privately held regenerative-medicine biotechnology company headquartered in Cambridge, Massachusetts, founded in 2017 to address the lack of scalable, reproducible manufacturing for personalized cell therapies. Its flagship Nebula™ platform is an AI-driven, closed-loop optical bioprocess that combines deep learning algorithms, label-free imaging, laser-based cell management, and the proprietary Cellinoverse in silico simulation environment on a modular, cassette-based hardware form factor. The platform targets the production of autologous induced pluripotent stem cell (iPSC) therapies for a broad range of chronic degenerative conditions including Parkinson's, diabetes, Alzheimer's, heart disease, kidney disease, and spinal cord injury, with a stated cost-reduction goal of approximately $10,000 per autologous iPSC line by 2030, down from a current $1–3 million baseline.

Cellino's business model is multi-streamed and pre-commercial. Non-dilutive R&D funding comes primarily from a $25 million, five-year ARPA-H NEBULA program award announced in September 2024, while venture capital is anchored by an $80 million Series A closed in January 2022 and led by Leaps by Bayer, 8VC, and Humboldt Fund. Commercial revenue is structured around strategic co-development partnerships with biopharma companies — notably Karis Bio for cardiovascular disease (April 2025) and Matricelf for spinal cord injury (March 2025) — which imply future milestone, licensing, and royalty streams rather than near-term product sales. Distribution is anchored by the U.S.'s first Nebula-powered iPSC Foundry, launched in February 2025, with a longer-term vision of hospital-based, on-demand cassette deployment under NEBULA and a direct patient waitlist on the company website.

Key competitive advantages include the FDA Advanced Manufacturing Technology (AMT) Designation received in May 2025 for its iPSC manufacturing technology, a substantial first-mover infrastructure position in U.S. autologous iPSC foundries, and an integrated AI stack that the company claims can suppress inter-donor variability in autologous tissue production. Risks are concentrated: a small number of biopharma partners and a single government program account for the bulk of near-term counterparties, the company remains pre-revenue with no published pricing, and the $10,000-per-line cost target — central to its investment thesis — has not yet been demonstrated at commercial scale.

Name

Cellino

Legal name

Cellino

Website

https://cellinobio.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Cellino builds the AI-driven Nebula platform for scalable, autologous iPSC biomanufacturing of personalized regenerative cell therapies, serving biopharma partners, hospitals, and ultimately patients with chronic degenerative diseases.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Biomanufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)

Keywords

• IPSC biomanufacturing
• Regenerative medicine
• Cell therapy manufacturing
• Autologous cell therapy
• Bioprocess automation

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Government R&D grants (ARPA-H): Non-dilutive funding awarded by ARPA-H ($25M over five years under NEBULA) to support development of autonomous biomanufacturing; effectively functions as development-stage revenue tied to milestone delivery.
2. Strategic co-development partnerships with biopharma: Cellino partners with biopharma companies (e.g., Karis Bio for cardiovascular iPSC therapy) to co-develop Nebula-powered autologous iPSC therapies, implying future milestone payments, licensing, or royalty streams.
3. Future autologous iPSC therapy commercialization: Long-term commercial intent to deliver personalized regenerative therapies to patients at scale, targeting a per-line cost reduction from $1–$3 million to ~$10,000 by 2030, implying eventual per-treatment or per-line revenue.

Pricing tiers

Go-to-market motion4 records

Distribution channels3 records

Marketing channels6 records

Core offering

Cellino builds the Nebula™ platform, an AI-driven, closed-loop optical biomanufacturing system for producing autologous iPSC-based regenerative cell, tissue, and organ replacement therapies. The platform combines deep learning, label-free imaging, laser-based cell management, and the Cellinoverse in silico simulation environment, deployed through cassette-based hardware at centralized foundries or in hospitals. The company pursues co-development partnerships with biopharma and, longer term, intends to commercialize per-patient autologous therapies, targeting a reduction in cost per iPSC line from $1–3 million to ~$10,000 by 2030.

Product overview

Cellino offers a single unified automated biomanufacturing platform, the Nebula™ Platform, composed of tightly integrated modules: Deep Learning (AI algorithms for reproducible biomanufacturing), Cellinoverse (in silico simulation of bioprocess behavior), Laser Cell Management (laser-based cell-density control), and the Optical Bioprocess (closed-loop, image-guided bioprocess control). Together these modules power the Nebula-Powered iPSC Foundry, the first U.S.-based foundry for scalable autologous biomanufacturing, enabling patient-specific regenerative therapies for conditions such as Parkinson's, diabetes, heart disease, Alzheimer's, kidney disease, and spinal cord injury.

Differentiator

Problem solved

Functional benefit

Brands

• Nebula: The company's proprietary AI-driven, modular, cassette-based biomanufacturing platform that compresses traditional infrastructure into scalable systems for producing personalized regenerative cell therapies (iPSC).

Products and services

• Nebula™ Platform Cellino's flagship modular, cassette-based biomanufacturing platform that compresses traditional cell-therapy infrastructure to enable scalable, distributed production of autologous iPSC-based regenerative medicines, deployable as large foundries or in hospitals. It is sold/licensed through co-development partnerships with biopharma and is targeted at hospitals for future point-of-care manufacturing.
• Nebula-Powered iPSC Foundry Facility-level deployment of the Nebula platform for scalable autologous biomanufacturing, launched as the U.S.'s first Nebula-Powered iPSC Foundry in February 2025. Operationalizes the Nebula platform as a centralized production and partnership hub serving biopharma co-development partners and future hospital customers.
• NEBULA Hospital-Based Personalized Cell Therapy Manufacturing Program Government-funded program under ARPA-H NEBULA to enable hospitals and healthcare facilities to deploy Nebula cassettes for on-demand, point-of-care production of personalized autologous cell therapies targeting heart disease, Parkinson's, and diabetes.

Quantifiable outcome

• Targeted cost reduction from $1–$3 million to approximately $10,000 per autologous iPSC line by 2030
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Partnerships

Three partnerships are on record, tiered core technology/clinical research partner, core co-development partner for first nebula-powered cardiovascular therapy and core co-development partner for spinal cord injury pipeline.

• Polyphroncore technology/clinical research partnerStrategic or Co-development Partner · 7 April 2026Polyphron and Cellino jointly published results showing Polyphron's platform can manufacture structured human tissue across genetically diverse patient-derived iPSC lines without re-optimizing per donor, validating scalability of autologous tissue manufacturing via computational optimization.
• Karis Biocore co-development partner for first nebula-powered cardiovascular therapyStrategic or Co-development Partner · 15 April 2025Cellino announced a partnership with Karis Bio to develop the first Nebula™-powered autologous iPSC therapy for cardiovascular disease. The partnership leverages Cellino's automated iPSC biomanufacturing platform to produce patient-specific regenerative therapies.
• Matricelfcore co-development partner for spinal cord injury pipelineStrategic or Co-development Partner · 11 March 2025Cellino and Matricelf announced a global collaboration to scale personalized spinal cord injury treatments using Cellino's Nebula platform for autologous iPSC manufacturing combined with Matricelf's spinal cord regeneration technology.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• ElevateBio: ElevateBio operates a hub-and-spoke cell and gene therapy platform combining process development and cGMP manufacturing capacity (BaseCamp) with internal therapeutic programs. Its integrated manufacturing-plus-pipeline model closely mirrors Cellino's foundry-plus-co-development strategy for regenerative cell therapies.
• RoslinCT: RoslinCT (formerly Roslin Cells) is a cell therapy contract development and manufacturing organization specializing in iPSC-derived cell therapies, including clinical-grade iPSC line production. It directly competes with Cellino on scalable iPSC manufacturing for clinical and commercial regenerative medicine applications.
• Ori Biotech: Ori Biotech is a London-based cell and gene therapy manufacturing platform company building automated, closed-system bioprocessing hardware for autologous and allogeneic therapies. It is one of the closest direct comparables to Cellino's Nebula platform given its focus on automation and scalability of personalized cell therapy manufacturing.
• bit.bio: bit.bio is a UK-based synthetic biology company developing a precision cellular reprogramming technology (opti-ox) to produce defined human cell types at scale for research and therapeutic use. It is a direct peer in iPSC-derived cell therapy manufacturing technology, though with a different reprogramming modality.

Broad incumbents

• Thermo Fisher Scientific: Thermo Fisher Scientific operates a sizable bioproduction and cell therapy services business, including cell therapy manufacturing capacity through its Patheon and Brammer Bio CDMO acquisitions. It is a broad incumbent competing across the full biomanufacturing stack where Cellino's Nebula platform aims to differentiate on automation and cost.
• Lonza Group: Lonza is a Swiss global CDMO with one of the largest cell and gene therapy manufacturing footprints worldwide, including dedicated autologous cell therapy facilities. It serves as a broad incumbent that competes with Cellino by offering outsourced cell therapy manufacturing services to biopharma at industrial scale.
• Cytiva (Danaher): Cytiva, a Danaher operating company, supplies bioprocessing equipment, consumables, and services for cell therapy manufacturing, including automation platforms. It overlaps with Cellino in the cell therapy bioprocess tooling market and is investing in closed, automated cell therapy manufacturing solutions.

Emerging players

• Culture Biosciences: Culture Biosciences offers cloud-based, automated bioreactor infrastructure for bioprocess development and scale-up. It is an emerging player with thematic overlap to Cellino's automated biomanufacturing vision, particularly in applying software and AI to cell culture process optimization, though focused on microbial/mammalian bioprocess rather than autologous iPSC therapies.
• Ginkgo Bioworks: Ginkgo Bioworks operates a synthetic biology platform combining automated lab infrastructure with cell programming capabilities for industrial and therapeutic applications. It is an emerging player with partial overlap to Cellino's automated, AI-driven cell engineering and biomanufacturing capabilities, though with a broader industrial biology scope.

Others

• Vineti: Vineti provides a cell and gene therapy orchestration and supply chain platform that manages the workflow, chain of identity, and chain of custody for personalized cell therapies. It is an adjacent ecosystem participant rather than a direct competitor, but its orchestration role is complementary to Nebula's manufacturing focus and could be integrated with Cellino's platform.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat5 records

Key risks7 records

Key highlights8 records

Customer concentration

• Xx.com/cellinobio

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellino